oseltamivir
E85057
Oseltamivir is an oral antiviral medication (commonly known by the brand name Tamiflu) used to treat and prevent influenza, including pandemic strains such as 2009 H1N1.
Observed surface forms (1)
| Surface form | Occurrences |
|---|---|
| Tamiflu | 2 |
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
antiviral drug
ⓘ
neuraminidase inhibitor ⓘ prodrug ⓘ small molecule ⓘ |
| approvedBy |
Food and Drug Administration
ⓘ
surface form:
U.S. Food and Drug Administration
|
| approvedForUseIn |
adults
ⓘ
children ⓘ |
| belongsToPharmacologicClass | neuraminidase inhibitors ⓘ |
| contraindicatedIn | patients with known hypersensitivity to oseltamivir ⓘ |
| developedBy |
Gilead Sciences (board member)
ⓘ
surface form:
Gilead Sciences
|
| hasAdministrationSchedule |
once daily for prophylaxis
ⓘ
twice daily for treatment ⓘ |
| hasATCCode | J05AH02 ⓘ |
| hasBioavailability | high oral bioavailability ⓘ |
| hasBlackBoxWarning | none (as of 2024, US) ⓘ |
| hasBrandName |
oseltamivir
self-linksurface differs
ⓘ
surface form:
Tamiflu
|
| hasChemicalFormula | C16H28N2O4 ⓘ |
| hasCommonSideEffect |
abdominal pain
ⓘ
diarrhea ⓘ headache ⓘ nausea ⓘ vomiting ⓘ |
| hasDrugClass |
anti-influenza agent
ⓘ
antiviral for systemic use ⓘ |
| hasEliminationRoute | renal excretion ⓘ |
| hasIndication |
post-exposure prophylaxis of influenza
ⓘ
uncomplicated acute illness due to influenza infection ⓘ |
| hasLegalStatus | prescription only ⓘ |
| hasMechanismOfAction |
inhibition of viral neuraminidase
ⓘ
prevents release of new influenza virions from infected cells ⓘ |
| hasPotentialAdverseEffect | neuropsychiatric events ⓘ |
| hasPregnancyCategory | C (US, historical classification) ⓘ |
| hasRouteOfAdministration |
oral
ⓘ
oral capsule ⓘ oral suspension ⓘ |
| hasTarget | influenza virus neuraminidase ⓘ |
| isListedOn | World Health Organization Model List of Essential Medicines ⓘ |
| isMostEffectiveWhen | started within 48 hours of onset of influenza symptoms ⓘ |
| isProdrugOf | oseltamivir carboxylate ⓘ |
| marketedBy | Roche ⓘ |
| usedFor |
prevention of influenza
ⓘ
prophylaxis of influenza A ⓘ prophylaxis of influenza B ⓘ treatment of 2009 H1N1 influenza ⓘ treatment of influenza ⓘ treatment of influenza A ⓘ treatment of influenza B ⓘ |
| wasWidelyUsedDuring | 2009 H1N1 influenza pandemic ⓘ |
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.
this entity surface form:
Tamiflu